ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

CDC Whistleblower Reveals Widespread Manipulation of Scientific Data and Top-Down Pressure on CDC Sc...

How Glutathione Can Save Your Life

Scientists discover how to 'switch off' autoimmune diseases

Reversing Neurodegeneration with a New Magnesium Compound

Gut Bacteria, Artificial Sweeteners and Glucose Intolerance

Brain inflammation dramatically disrupts memory retrieval networks, UCI study finds

Long-term use of pills for anxiety and sleep problems may be linked to Alzheimer's

Surprising discovery: HIV hides in gut, evading eradication

Clinical trial demonstrates safety, effectiveness of immunotherapy for AdV, BKV, and herpesviruses i...

Electric Current to Brain Boosts Memory

 
Print Page
Email Article

Major Late-Round Ampligen® Trial Recruits in Seven States

  [ 1726 votes ]   [ Discuss This Article ]
By Editor • www.ProHealth.com • November 29, 2006


An open label Phase III “intervention” study of the antiviral drug Ampligen® 511 - the most recent step in Hemispherx Biopharma’s decade-long quest for FDA approval of the drug as a CFS therapy - is recruiting subjects with “severely debilitating” CFS/ME at centers in seven states, nationwide, according to ClinicalTrials.gov.

Locations and Principal Investigators
The “chairs” or principal investigators of the trial, titled “An Open Label Study of Ampligen® in Chronic Fatigue Syndrome,” include three of the leading American names in CFS treatment:

n Daniel Peterson, MD, Sierra Internal Medicine, Incline Village, NV

n Lucinda Bateman, MD, Fatigue Consultation Clinic, Salt Lake City, UT

n Charles W. Lapp, MD, Hunter-Hopkins Center, Charlotte, NC

The other four listed trial locations include Los Altos, CA; Springfield, NJ; Philadelphia, PA; and Reston, VA.

Trial Design and Purpose
Hemispherx noted recently that a previous, not-yet-published Phase III (large) randomized placebo-controlled Ampligen® trial enabled the group of CFS patients who received the drug for twice weekly for 40 weeks to increase their exercise tolerance by an average of 15 percent compared with another group of CFS patients who were randomly selected to receive the placebo (fake dose).

The current trial, officially titled An Open Label Study of Ampligen® in Chronic Fatigue Syndrome (ClinicalTrials.gov Identifier: NCT00215813) will be:

n An expanded access (large-population) interventional trial to study and analyze in more detail the drug’s safety and effectiveness in affecting CFS symptoms among a large group of patients with “severely debilitating CFS/ME.”

n Open label, non-randomized, and uncontrolled. All patients will knowingly be receiving the drug Ampligen® (Poly I: Poly C12U). None will receive placebo.

n And importantly, the FDA has “approved the study for cost recovery.” This means patients enrolled in the study will be responsible for paying costs relating to the therapy – including the cost of the drug itself, and the cost of infusions, supplies, and diagnostic and other lab testing.

Though the trial-related costs are not specified, the drug is likely to be quite expensive if and when the FDA’s follow-up research supports approval of Ampligen® as a CFS therapeutic. Some project that the drug would cost $15,000 to $20,000 per patient per year, according to a recent article in Science News. (The co-inventor of Ampligen®, William A. Carter, MD, pioneered the clinical development of the antiviral therapy interferon, which now pulls down annual sales of $2 billion-plus.)

Eligibility and Inclusion Criteria:

Diagnosis
Diagnosis of Myalgic Encephalomyelitis (ME) as defined by the 1988 Centers for Disease Control and Prevention (CDC) case definition for Chronic Fatigue Syndrome (CFS); ongoing for at least 12 months. (Other clinical conditions which could present with similar symptoms must be excluded.)

Age Range
Ages 18 through 65.

Males or non-pregnant, non-lactating females
Females must be of non-child bearing potential (either post-menopausal for two years or surgically sterile including tubal ligation), or using an effective means of contraception (birth control pills, intrauterine device, diaphragm).

Females who are less than two (2) years post-menopausal, those with tubal ligations, and those using contraception must have a negative serum pregnancy test within the four (4) weeks prior to the first study medication infusion.

Females of child bearing potential agree to use an effective means of contraception from four (4) weeks prior to the baseline pregnancy test until four (4) weeks after the last study medication infusion.

Other
A reduced quality of life as determined by a Karnofsky performance score (KPS) of from 20 to 60 at baseline. The KPS must be rounded in increments of ten (10).

Ability to provide written informed consent indicating awareness of the investigational nature of this study.

Documentation (during baseline or historically following onset of CFS/ME) of:
n A negative antinuclear antibody test (ANA) or a negative anti-ds (double-stranded) DNA,
n A negative rheumatoid factor,
n And an erythrocyte sedimentation rate (ESR).

Documentation during baseline of a normal T4 (or other laboratory evidence that the subject is euthyroid [normal thyroid]) is also required.

Contact Information

Please refer to this study by ClinicalTrials.gov identifier NCT00215813

Sharon Conway 215-988-0080 sharon@hemispherx.net

Please contact Hemispherx Biopharma for additional information regarding trial locations and site contacts:

By Fax: 215/988-1739

E-mail: trialinfo@hemispherx.net

Mail: Hemispherx Biopharma, Inc. One Penn Center
1617 JFK Blvd., 6th Floor
Philadelphia, PA 19103

More Information
Study ID Numbers: AMP 511 Last Updated: October 24, 2006

Health Authority: United States: Food and Drug Administration ClinicalTrials.gov processed this record on 2006-10-27




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Free Shipping on Nutritional Supplement Orders

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Why Berries Offer a Rainbow of Health Benefits Why Berries Offer a Rainbow of Health Benefits
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing